As part of our ongoing commitment to ensuring that our tests evolve with the latest scientific research and clinical needs, we’ve updated the GeneSight Test. The enhancements are designed to give clinicians clearer, more comprehensive genetic insights when treating patients with mental health conditions.

“These enhancements to the GeneSight Test are based on a comprehensive analysis of peer-reviewed literature and reflect our continued commitment to providing clinicians with genetic insights,” said Brian Donnelly, Chief Commercial Officer, Myriad Genetics.

The GeneSight Test is the most widely used pharmacogenomic test in mental health. It provides information on how a patient’s genes may influence their metabolism or response to more than 60 psychiatric medications commonly prescribed for depression, anxiety, ADHD, and other conditions.

With these upgrades, clinicians can get even more information to help inform treatment plans, and use of the GeneSight Test may help shorten your patients’ road to wellness.

New Medications Added for Tardive Dyskinesia

One of the most notable updates is the inclusion of two medications that treat tardive dyskinesia, a movement disorder that can develop after long-term use of certain medications, especially antipsychotics.

These additions—valbenazine (Ingrezza®) and deutetrabenazine (Austedo®)—help expand the test’s clinical utility.

As awareness grows around tardive dyskinesia and its impact on patients’ quality of life, incorporating medications specifically used to manage it reinforces the GeneSight Test’s value in supporting more individualized psychiatric care.

Updated Gene Variants and Medication Categorization

We updated several gene variants — CYP3A4, HTR2A, and UGT2B15. These genes play roles in how the body metabolizes or responds to various medications, and keeping this information aligned with the latest peer-reviewed science helps to ensure that clinicians are receiving the most current guidance.

Beyond genetic updates, we also revised how certain antipsychotic and anxiolytic/hypnotic medications are categorized. These changes stem from a fresh review of existing clinical. This kind of ongoing refinement is critical in a field where evidence evolves quickly and patient outcomes can be significantly influenced by prescribing decisions.

Improvements to the GeneSight MTHFR Report

Changes aren’t limited to the psychotropic test. We have also enhanced the GeneSight MTHFR report, adding new information intended to improve clarity and make it easier for clinicians to interpret results. The updated design now aligns visually with the GeneSight Psychotropic report, creating a more consistent and intuitive experience for healthcare providers who use both.

The updated GeneSight Test is available immediately for prescribing clinicians. For more information, visit genesight.com/for-clinicians.

Our articles are for informational purposes only and are reviewed by our Medical Information team, which includes PharmDs, MDs, and PhDs. Do not make any changes to your current medications or dosing without consulting your healthcare provider.

The GeneSight test must be ordered by and used only in consultation with a healthcare provider who can prescribe medications. As with all genetic tests, the GeneSight test results have limitations and do not constitute medical advice. The test results are designed to be just one part of a larger, complete patient assessment, which would include proper diagnosis and consideration of your medical history, other medications you may be taking, your family history, and other factors.

If you are a healthcare provider and interested in learning more about the GeneSight test, please contact us at 855.891.9415. If you are a patient, please talk with your doctor to see if the GeneSight test may be helpful.


Published: February 11, 2026
Chat